MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?

Zacks
Zacks kaynağında aç
MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?

MediWound (MDWD) shares soared 6.1% in the last trading session to close at $14.2. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.8% gain over the past four weeks.

The stock price gain likely reflects MediWound’s broader optimism about the commercial prospects of NexoBrid, its marketed therapy for enzymatic eschar removal in patients with deep partial- and full-thickness thermal burns. The product has demonstrated solid commercial momentum, supported by growing hospital adoption and record quarterly revenue and unit sales in the second quarter. Investors may also be encouraged by progress with EscharEx, an investigational therapy for debridement of chronic wounds, which is also advancing through a late-stage study for venous leg ulcers.

This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of -175%. Revenues are expected to be $7.63 million, up 40.4% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For MediWound, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MDWD going forward to see if this recent jump can turn into more strength down the road.

 

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

MediWound is part of the Zacks Medical - Drugs industry. Korro Bio, Inc. (KRRO), another stock in the same industry, closed the last trading session 4.8% higher at $16.62. KRRO has returned 62.5% in the past month.

Korro Bio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.14. Compared to the company's year-ago EPS, this represents a change of +40.6%. Korro Bio, Inc. currently boasts a Zacks Rank of #3 (Hold).

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
MediWound Ltd. (MDWD): Free Stock Analysis Report
 
Korro Bio, Inc. (KRRO): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research